Market Overview:

Oral typhoid vaccine is a live attenuated bacterial vaccine against typhoid fever caused by Salmonella Typhi bacteria. The oral typhoid vaccine stimulates mucosal and systemic immunity and offers longer lasting protection compared to parenteral vaccines. It is specifically designed for mass immunization programs in developing countries where typhoid is highly endemic. The vaccine provides affordable protection against typhoid fever and helps lower disease and economic burden in endemic regions. Compared to injectable vaccines, oral vaccines offer advantages of easy administration and do not require trained healthcare professionals.

The global Oral Typhoid Vaccine Market is estimated to be valued at US$ 394.62 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Explorer more information on this topic, Please visit @ https://www.coherentmarketinsights.com/industry-reports/oral-typhoid-vaccine-market

Market key trends:

The rising prevalence of typhoid fever especially across Asia Pacific and Latin American countries is a key factor fueling demand for oral typhoid vaccines. As per WHO, typhoid fever affects over 20 million people annually across the globe with over 200,000 deaths. Developing nations account for majority of cases. High disease burden in endemic regions along with WHO recommendation for inclusion of oral typhoid vaccine in routine vaccination programs in these regions is expected to drive higher adoption and uptake of oral typhoid vaccines. Another key trend is development of improved oral typhoid vaccines with higher efficacy, longer duration of protection and thermostability without cold chain requirements. Such innovative vaccines are gaining regulatory approvals and commercial availability which will augment the oral typhoid vaccine market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The oral typhoid vaccine market presents moderate threat of new entrants due to the presence of stringent regulations for vaccine development and testing.
Bargaining power of buyers: The bargaining power of buyers is high owing to the presence of a large number of established players offering affordable generic vaccines.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of substitute raw material sources.
Threat of new substitutes: New substitute vaccines with improved efficacy profiles offer moderate threat.
Competitive rivalry: High

Key Takeaways

The global oral typhoid vaccine market is expected to witness high growth, exhibiting a CAGR of 12% over the forecast period, due to increasing prevalence of typhoid fever.

Regional analysis: Asia Pacific dominates the global market and is expected to grow at the fastest CAGR during the forecast period owing to large population base, increasing awareness about vaccines, and improving healthcare infrastructure in major countries like India and China.

Key players operating in the oral typhoid vaccine market are Sanofi Pasteur, Bharat Biotech, Pfizer Inc., GlaxoSmithKline (GSK), Baxter International Inc., Merck Co., Inc. (MSD outside North America), Takeda Pharmaceutical Company Limited, Novartis International AG, Biological E. Limited, AstraZeneca, Cipla Limited, Prokarium, Bio-Med Pvt. Ltd., Panacea Biotec, Dynavax Technologies Corporation, Butantan Institute, Zydus Cadila, Biomed Pvt. Ltd., Cadila Healthcare Limited, GlaxoSmithKline Biologicals.

*Note:

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it